Topics:
Thoracic Malignancies • Medical Oncology
How do you treat patients with stage III squamous cell carcinoma of the lung with persistent/progressive disease despite concurrent chemoradiation?
How would you utilize PD-L1 expression to guide your decision making in this situation?
Answer from: Medical Oncologist at Academic Institution
In patients with persistent disease without true radiographic progression outside the radiation fields, proceeding with consolidation durvalumab per the PACIFIC trial is reasonable. The robust benefits of durvalumab in the PACIFIC trial were likely from treatment of both persistent and micrometastat...
Sign in or Register to read more